CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increasing awareness of genetic diseases and personalised medicine
4.1.2. Increasing demand for genome analysis in animal and plant livestock
4.1.3. Technological advancements & decreasing prices of DNA sequencing
4.1.4. Growing importance of SNP (Single Nucleotide Polymorphism) genotyping
4.2. Market Restraints & Challenges
4.2.1. Reimbursement issues
4.2.2. Lack of well-trained personnel
4.2.3. Increasing market consolidation
4.3. Market Opportunities
4.3.1. Increasing investments and application areas of genotyping
4.3.2. Growing demand for affordable genotyping services
CHAPTER 5. GLOBAL GENOTYPING MARKET– BY PRODUCT& SERVICES
5.1. Instruments
5.1.1. Sequencers & Amplifiers
5.1.2. Analyzers
5.2. Reagents & Kits
5.3. Bioinformatics Software
5.4. Genotyping Services
CHAPTER 6. GLOBAL GENOTYPING MARKET – BY TECHNOLOGY
6.1. PCR (Polymerase Chain Reaction)
6.1.1. Real-Time PCR
6.1.2. Digital PCR
6.2. Sequencing
6.2.1. Next Generation Sequencing
6.2.2. Sanger Sequencing
6.2.3. Pyrosequencing
6.3. Capillary Electrophoresis
6.3.1. Restriction Fragment Length Polymorphism
6.3.2. Amplified Fragment Length Polymorphism
6.3.3. Single Strand Conformation Polymorphism
6.4. Microarray
6.5. Allele-Specific Oligonucleotide Probes
6.6. Others
CHAPTER 7. GLOBAL GENOTYPING MARKET – BY APPLICATION
7.1. Animal Genetics
7.2. Diagnostics Research
7.3. Agricultural Biotechnology
7.4. Pharmacogenomics
7.5. Others
CHAPTER 8. GLOBAL GENOTYPING MARKET – BY END USER
8.1. Biopharmaceutical & Biotechnology Companies
8.2. Research Laboratories and Institutes
8.3. Others
CHAPTER 9. GLOBAL GENOTYPING MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL GENOTYPING MARKET - COMPANY PROFILES
10.1. QIAGEN N.V.
10.2. GE Healthcare
10.3. Roche Diagnostics
10.4. Beckmann Coulter, Inc.
10.5. Fluidigm Corporation
10.6. Sequenom, Inc.
10.7. Agilent Technologies, Inc.
10.8. Thermo Fisher Scientific
10.9. Affyemetrix Inc.
10.10. Illumina Inc.
10.11. Oxford Nanopore Technologies
10.12. Intellia Therapeutics, Inc.
10.13. Harlan Laboratories
10.14. Life Technologies Corporation
CHAPTER 11. GLOBAL GENOTYPING MARKET - COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
